Two analyses presented during the American Society of Clinical Oncology’s 2016 Gastrointestinal Cancers Symposium evaluated the results of second-line treatment following treatment with a combination of Abraxane (paclitaxel protein-bound particles for injectable suspension; albumin-bound) and gemcitabine in first-line metastatic pancreatic cancer patients.
The Biden administration has left NIH in a weakened state, intensifying politicization of science on Capitol Hill and eroding the bipartisan support the government’s premier biomedical research agency has traditionally enjoyed.
